Furthermore, the prospect of targeting galectin-3 presents a novel therapeutic strategy for cardiovascular diseases by mitigating cardiac fibrosis, hypertrophy, and inflammation [72,80]. This evidence concerns the gene LGALS3 and fibrosis.